Chantix Recall Expanded To U.S. Products Due To N-Nitroso Varenicline Contamination

Following a recent announcement that Pfizer would halt production of the stop-smoking drug Chantix, due to the presence of potentially cancer-causing chemicals, the manufacturer has announced a recall for 12 lots of the drug sold in the United States.

The FDA announced the Chantix recall on July 19, indicating batches of the drug contain levels of a chemical known as N-nitroso-varenicline at amounts which exceed an Acceptable Daily Intake (ADI) level set by Pfizer itself. While unverified, it is believed the chemical is a cancer risk to humans.

Chantix (varenicline) is a prescription medication introduced by Pfizer in 2006, designed to help people quit smoking. However, less than three years after its release, the FDA required Pfizer to add a “black box” warning, following a number of reports involving suicide and other unusual behavior among users. The FDA rescinded the label requirement and removed the warning in December 2016.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The recall comes after the manufacturer announced it was halting Chantix distribution in June, when the drug became the latest linked to a class of cancer-causing chemicals known as nitrosamines. It announced a recall in Canada at the time, but not one in the United States.

Over the last few years, several drugs, such as Zantac, valsartan and metformin, have faced similar recalls, primarily to do the presence of a nitrosamine known as N-Nitrosodimethylamine (NDMA).

Pfizer indicates it has received no reports of adverse events linked to this recall, and the FDA is not calling on users to stop taking the drug.

“Long-term ingestion of N-nitroso-varenicline may be associated with a theoretical potential increased cancer risk in humans, but there is no immediate risk to patients taking this medication,” Pfizer said in the recall announcement. “The health benefits of stopping smoking outweigh the theoretical potential cancer risk from the nitrosamine impurity in varenicline.”

The recall for Chantix affects two lots of 0.5 mg Tablets, two lots of 1 mg Tablets, and eight lots of a Chantix kit of 0.5/1 mg Tablets. A complete list of NDCs, lot numbers and expiration dates are included in the recall notice.

Pfizer has instructed wholesalers and distributors to stop use and distribution of these products and quarantine them immediately. They, and patients, have been instructed to contact Stericycle at 888-276-6166 for information on how to return the product and obtain a reimbursement.

Those who received free Chantix through the Pfizer Patient Assistance Protram (PAP) or the Pfizer Institutional Patient Assistance Program (IPAP) have been instructed to request replacement product by calling 833-203-2776.

1 Comments

  • KarimOctober 19, 2021 at 8:16 pm

    Last April I was advised by my doctor to take one box of CHANTIX 0.5/1.0 mg for one month and two boxes of CHANTIX 1.0 mg for two months supply to quit smoking, so I bought them from CVS in Miami, they cost mi almost a fortune, I already finished all of the three months tablets, I am worried about what I am reading today about CHANTIX since my three boxes are from the lots that Pfizer recalled fro[Show More]Last April I was advised by my doctor to take one box of CHANTIX 0.5/1.0 mg for one month and two boxes of CHANTIX 1.0 mg for two months supply to quit smoking, so I bought them from CVS in Miami, they cost mi almost a fortune, I already finished all of the three months tablets, I am worried about what I am reading today about CHANTIX since my three boxes are from the lots that Pfizer recalled from the market.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Depo-Provera Brain Tumor Warnings Added to Drug Label in Europe, But Not In U.S.
Depo-Provera Brain Tumor Warnings Added to Drug Label in Europe, But Not In U.S. (Posted 2 days ago)

A recently filed Depo-Provera lawsuit questions why Pfizer updated the drug label in Europe, to warn about the risk of meningioma brain tumors, but failed to provide the same Depo-Provera warnings to U.S. consumers and doctors.

Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week
Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week (Posted 4 days ago)

U.S. District Judge presiding over all federal hair relaxer lawsuits will meet with lawyers involved in the litigation on Thursday, to discuss the status of the claims and when to move forward with bellwether cases.